SEARCH:   Advanced

Blood, 15 December 2006, Vol. 108, No. 13, pp. 4163-4169. Prepublished online as a Blood First Edition Paper on August 10, 2006; DOI 10.1182/blood-2006-04-017632. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-017632v1 108/13/4163    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dupuis, J. Articles by Gaulard, P. Search for Related Content PubMed PubMed Citation Articles by Dupuis, J. Articles by Gaulard, P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 25, 2006 Accepted July 27, 2006 Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Goupe d’ Eude des Lmphomes de l’ Adulte (GELA) study Jehan Dupuis, Jean-Francois Emile, Nicolas Mounier, Christian Gisselbrecht, Nadine Martin-Garcia, Tony Petrella, Reda Bouabdallah, Francoise Berger, Alain Delmer, Bertrand Coiffier, Felix Reyes, and Philippe Gaulard* Hopital Henri Mondor, AP-HP, Creteil, France Hopital Ambroise Pare, AP-HP, Boulogne, France Hopital Saint Louis, AP-HP, Paris, France Dijon University Hospital, Dijon, France Institut Paoli-Calmettes, Marseille, France Centre Hospitalier Lyon-Sud, Pierre-Benite, France Reims University Hospital, Reims, France * Corresponding author; email: philippe.gaulard{at}hmn.aphp.fr. Peripheral T-cell lymphomas (PTCLs) are rare and have a dismal prognosis. The most frequent subtype is PTCL, unspecified. Epstein - Barr virus (EBV) has been detected in around 40% of cases, but its prognostic significance is not fully established. Lymph node samples from 110 patients with PTCL, unspecified included in LNH87 and LNH93 trials were available. EBV status was studied by EBER In Situ Hybridization (EBER-ISH). EBER-ISH showed positive cells in 45/110 patients (41%). Pretreatment characteristics were comparable between positive and negative cases, except for male gender (80% versus 60% respectively, p=0.02). Only 50% of patients achieved complete remission with a 5 year event-free survival (EFS) and overall survival (OS) of 21% and 30%. EBER-ISH positivity was the sole factor linked with worse EFS with a 5 year probability of 11% for positive patients. In univariate analysis, factors affecting OS were EBER-ISH positivity, high LDH level and age >60 years. In multivariate analysis, EBER-ISH was associated with a worse OS in the elderly population. Time-dependent analysis showed that the negative impact of EBV was essentially seen in the first 2 years following diagnosis. These results warrant further studies regarding pathogeny and specific treatment approaches for EBV-associated PTCL patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020